Loading...
Market
What disease will the first drug discovered using Exscientia's GenAI platform target by the end of 2024?
2
Resolution / Starting Odds
Cancer • 25%
Cardiovascular disease • 25%
Neurological disorder • 25%
Other • 25%
Official announcements from Exscientia or relevant regulatory bodies
Story
Exscientia Launches AWS-Powered GenAI Platform for Drug Discovery
Jul 10, 2024, 11:13 AM
Exscientia has launched a state-of-the-art GenAI platform to advance drug discovery, built using AWS technology. The platform integrates generative AI drug design and robotic lab automation to accelerate the delivery of high-quality drugs at faster speeds and lower costs. This development signifies a significant shift in the drug discovery landscape, leveraging massive proprietary datasets and AI to produce intelligence that leads to drug production. Jensen Huang highlighted the scale of data and compute reaching an inflection point in this field.
View original story
Similar markets
Cancer • 25%
Cardiovascular disease • 25%
Neurological disorder • 25%
Other • 25%
Cancer • 25%
Autoimmune disorders • 25%
Infectious diseases • 25%
Other • 25%
Cardiovascular • 25%
Oncology • 25%
Neurology • 25%
Other • 25%
Cancer • 25%
Infectious Diseases • 25%
Autoimmune Diseases • 25%
Other • 25%
Cancer • 25%
Neurodegenerative Diseases • 25%
Cardiovascular Diseases • 25%
Other • 25%
Cancer • 25%
Neurological disorders • 25%
Infectious diseases • 25%
Other • 25%
Cancer treatment • 25%
Neurodegenerative disease treatment • 25%
Cardiovascular disease treatment • 25%
Other • 25%
Insilico Medicine • 25%
Amgen • 25%
Nested Therapeutics • 25%
Other • 25%
Cancer • 25%
Cardiovascular diseases • 25%
Neurological disorders • 25%
Other • 25%
Google DeepMind • 25%
Microsoft • 25%
IBM • 25%
Other • 25%
Respiratory drug • 25%
Immunology drug • 25%
Vaccine • 25%
Other • 25%
